Akis (diclofenac injection) / IBSA Institute Biochemical SA 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


123»
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Clinical, Journal, HEOR, Cost-effectiveness:  Cost-Effectiveness of Team-Based Coaching With Surveillance for Prevention of Acute Kidney Injuries. (Pubmed Central) -  Apr 2, 2025   
    More than 10% of US patients undergoing endovascular procedures experience contrast-associated acute kidney injuries (AKIs), resulting in increased costs and health deficits...In this economic evaluation of implementation strategies for AKI prevention, virtual learning collaborative with automated surveillance reporting was the economically preferred intervention and was estimated to decrease AKI likelihood, permanent kidney disease, and their associated costs after undergoing cardiac catheterization. These results may be generalizable to other endovascular procedures and practice-changing protocols or checklists implementation efforts.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Review, Journal:  Advances in the Design, Discovery, and optimization of aurora kinase inhibitors as anticancer agents. (Pubmed Central) -  Mar 17, 2025   
    The integration of artificial intelligence and computational approaches is poised to accelerate the development of AKIs as anticancer agents. However, the associated challenges currently hindering its impact in drug development must be overcome before drugs can successfully translate from early drug development into clinical practice.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Review, Journal:  Acute Kidney Injury Secondary to Hypertension-Related Thrombotic Microangiopathy: A Case Report and Literature Review. (Pubmed Central) -  Nov 15, 2024   
    The presence of acute kidney injuries (AKIs) in adults with microangiopathic hemolytic anemia and thrombocytopenia poses diagnostic and therapeutic challenges, as there are numerous causes that cannot always be rapidly differentiated...We report a case of AKI secondary to hypertension-related thrombotic microangiopathy and describe the clinical course from presentation to diagnosis and treatment. The patient remained hemodialysis-dependent despite attempts to control the blood pressure and administer anticomplement treatment.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Retrospective data, Journal:  Longitudinal Changes in Estimated Glomerular Filtration Rate Following Repeat Heart Transplant in Children and Young Adults. (Pubmed Central) -  Oct 16, 2024   
    Therefore, it is recommended that DI-AKI be recognized early to enable dose reduction or even drug suspension, depending on the type of reaction, to reduce healthcare costs and improve clinical outcomes for patients. This study provides data on longitudinal changes in eGFR over 6?years and finds that female sex and repeat HT recipients with greater 2 AKIs between transplants are at greatest risk for CKD3 presence post-RT.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Rhabdomyolysis-related acute kidney injury in patients with COVID-19. (Pubmed Central) -  Sep 26, 2024   
    Rhabdomyolysis was present in 13.0% of the patients who had AKI during COVID-19 infection. Rhabdomyolysis-related AKI is more proinflammatory and has a more mortal clinical course.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Acute Kidney Injury Duration and 20-Year Risks of CKD and Cardiovascular Disease. (Pubmed Central) -  May 20, 2024   
    AKIs were categorized as rapid reversal AKI (?48 hours), persistent AKI (2-7 days), and acute kidney disease (AKD) (>7 days)...However, persistent AKI was associated with a slightly increased aHR of heart failure (1.09; 95% CI, 1.02-1.16), and aHRs of heart failure, ischemic heart disease, and peripheral artery disease were slightly increased for AKD (1.09 [95% CI, 1.03-1.15], 1.11 [95% CI, 1.03-1.19], and 1.10 [95% CI, 1.02-1.17], respectively). AKI duration was associated with development of CKD, but not overall CVD; however, rates of heart failure, ischemic heart disease, and peripheral artery disease increased slightly with AKI duration.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal, Real-world evidence, Real-world:  Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data. (Pubmed Central) -  Feb 6, 2024   
    Particular attention should be directed toward monitoring renal function in individuals receiving anticoagulants, including warfarin and direct oral anticoagulants, as well as other anticoagulant agents. This diligence is particularly imperative within the first month after anticoagulant administration for individuals with a tendency for AKI.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Review, Journal:  From Physiology to Pathology: The Role of Mitochondria in Acute Kidney Injuries and Chronic Kidney Diseases. (Pubmed Central) -  Oct 30, 2023   
    Numerous studies have demonstrated the important role of mitochondria in maintaining normal kidney function and in the pathogenesis of various renal diseases, including acute kidney injuries (AKIs) and chronic kidney diseases (CKDs)...This review provides an updated overview of mitochondrial homeostasis under physiological conditions and the involvement of mitochondrial dysfunction in renal diseases. Finally, we summarize the current status of mitochondria-targeted strategies in attenuating renal diseases.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal, Surgery:  Perioperative Intravenous Amino Acid Infusion in Major Urologic Surgery. (Pubmed Central) -  Oct 28, 2023   
    PO-AKIs were much higher in the crystalloid group compared to the AA group (34 vs. 17, p = 0.022) due to a lower incidence of KDIGO I and II in the AA group (14 vs. 30 p = 0.016)...The hospital length of stay was higher in the crystalloid group (p < 0.05) with a consequent saving in hospital costs. Perioperative AA infusion may help reduce the incidence of PO-AKI after major urological minimally invasive surgery.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Review, Journal:  Pathway from Acute Kidney Injury to Chronic Kidney Disease: Molecules Involved in Renal Fibrosis. (Pubmed Central) -  Oct 2, 2023   
    Risk factors mentioned in AKI progression to CKD are frequency and severity of kidney injury, chronic diseases such as uncontrolled hypertension, diabetes mellitus, obesity and unmodifiable risk factors (i.e., genetics, older age or gender). To provide a better understanding of AKI transition to CKD, we have selected relevant and updated information regarding the risk factors responsible for AKIs unfavorable long-term evolution and mechanisms incriminated in the progression to a chronic state, along with possible therapeutic approaches in preventing or delaying CKD from AKI.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal, Adverse events:  Nirmatrelvir/ritonavir (Paxlovid (Pubmed Central) -  Apr 4, 2023   
    A case-by-case multidisciplinary approach including a clinical pharmacologist is required in these complex situations. Blood pressure elevation, confusion, cutaneous reactions and AKIs were the main unexpected ADRs of interest to follow, but need to be confirmed with a qualitative approach over time and new reports.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Stent vs Stent-less Ileal Conduits After Radical Cystectomies: Is There Difference In Early Postoperative Outcomes (S404C) -  Mar 30, 2023 - Abstract #AUA2023AUA_2894;    
    This study represents the largest multi-institutional analysis comparing outcomes between traditionally stented and stent-less RCICs, and shows that there is no significant difference in outcomes. This study shows no difference in significant perioperative complications in patients without stents compared to those with stents.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Predicting Risk for Patients Undergoing Sacrocolpopexy from Frailty Indexes (S401A) -  Mar 30, 2023 - Abstract #AUA2023AUA_1489;    
    The RAI-rev is a better predictor than the mFI-5 for major complications, readmission rate, mortality, and hospital LOS and may help in the decision making and risk counseling for patients POP considering an SCP. SOURCE OF
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Leveraging modern machine learning tools to predict outcomes of in-patient acute kidney injury () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_849;    
    Results 15% of all identified AKIs culminated in death, 4% required ITU, and 1.5% were dialysed on a renal unit...These steps include expanding the number of cases and variables used for training, improving outcome labelling, and adjusting model architecture. If validated following fine tuning, this model can improve AKI care whilst streamlining the use of healthcare related resources.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Acute Kidney Injury Complicating Severe Acute Pancreatitis: Clinical Profile and Factors Predicting Mortality. (Pubmed Central) -  Dec 27, 2022   
    SAP-AKI constituted 2.14% (68 of 3,169) of all AKIs with 1.5%, 20.6%, and 77.9% in Kidney Disease Improving Global Outcomes (KDIGO) Stages I, II and III respectively...The overall mortality was 33.8%. Necrotizing pancreatitis, circulatory failure, peak creatinine >3 mg/dL, BISAPs >3, KDIGO III, and the need for kidney replacement therapy were independent risk factors for mortality.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Urine Mass Spectrometry Can Distinguish Prerenal and Intrarenal AKI (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3429;    
    Additional sampling will enable the use of machine learning algorithms to classify the kidney disease that is present. Further correlation of the different analytes in prerenal and intrarenal AKIs is needed, however this study shows the potential utility of mass spectrometry to rapidly phenotype AKI in the clinical setting.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Is COVID-19 Infection Associated With the Progression of Kidney Disease? Findings From a Population Based Observational Study From British Columbia, Canada (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2757;    
    Together the inflammation caused by the virus in the kidneys and the episodes of AKIs are risk factors for progression of kidney diseases...Conclusion COVID-19 infection in non-dialysis CKD patients appeared to be associated with higher risk of progression to kidney failure. Although not statistically significant, the substantial increase in risk estimate warrants close monitoring of kidney function among CKD patients after COVID-19 infection.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal, CAR T-Cell Therapy:  Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. (Pubmed Central) -  Sep 30, 2022   
    AKIs were commonly related to CRS and high peak inflammatory cytokine levels. CAR T-cell therapy is feasible in ESRD patients and requires careful planning of lymphodepletion.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Akis (diclofenac injection) / IBSA Institute Biochemical SA
    BUT WHAT ABOUT THE RASH? (Convention Center Exhibit Hall: Rapid Area 4B) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3523;    
    CASE PRESENTATION: A 74-year-old woman with Crohn's disease (on weekly adalimumab); pulmonary hypertension (RVSP 76 mmHg); OHS/OSA, on home BPAP 17/7 cmH2O; and morbid obesity presented with a one-week history of skin lesions...She was hypoxic during the visit and given doxycycline for empiric treatment of pneumonia...Labs were significant for a leukocytosis of 19.3 with left shift, lactate of 3.5, serum creatinine of 1.9 (likely higher than patient's previous baseline of 1.7 with previous history of recurrent AKIs on CKD), elevated inflammatory markers, and normal ALT/AST...She was treated empirically with vancomycin, piperacillin-tazobactam, valacyclovir, and amphotericin B, the latter given the concern of blastomycosis... Prompt recognition of multiorgan failure secondary to blastomycosis is important for early treatment and improved survival in immunocompromised patients
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases. (Pubmed Central) -  Jul 23, 2022   
    To estimate the frequency of drug-induced AKIs (both CA-AKIs and HA-AKIs) observed in a French university hospital, we applied the capture-recapture method to 1) the French national pharmacovigilance database (FPVD) and 2) a cohort of hospitalized patients with drug-induced AKIs (documented by analyzing the French national hospital discharge database and the patients' electronic medical records)...The frequency of drug-induced AKI is relatively high and is probably underestimated. The clinical management of an AKI might depend on where it originated.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Clinical, Journal:  Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries. (Pubmed Central) -  Jul 16, 2022   
    The clinical management of an AKI might depend on where it originated. In view of the long-term impact of AKI on the kidneys and the differences between our CA-AKI and HA-AKI subgroups, our present results are interesting for optimizing treatments, limiting the occurrence of CA- and HA-AKIs, and (ultimately) reducing healthcare costs.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Late-Onset Acute Kidney Injury is a Poor Prognostic Sign for Severe Burn Patients. (Pubmed Central) -  May 20, 2022   
    AKI was diagnosed according to Kidney Disease Improving Global Outcomes (KDIGO) criteria (2012), and it was divided into early and late AKIs depending on its onset time (within the first 3 days or >3 days post burn)...AKI remains prevalent and is associated with high mortality in severely burned patients. Late-onset acute kidney injury had greater severity and worse prognosis.
  • ||||||||||  Akis (diclofenac injection) / IBSA Institute Biochemical SA
    Journal:  Trust Versus Content in Multi-functional Land Management: Assessing Soil Function Messaging in Agricultural Networks. (Pubmed Central) -  May 12, 2022   
    The source of the messages was important when it came to the implementation of farm management actions. Two pathways for enhanced farmer uptake of multi-functionality are proposed that have wider application are; to increase trust between farmers and actors that are agents of multi-functional messages and/or to increase the bundling or multi-functionality of messages (mandate) of actors trusted by farmers.